Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas

Vincent A. van Vugt; David E. Piccioni; Bradley D. Brown; Tiffany Brown; Marlon G. Saria; Tiffany Juarez; Santosh Kesari

doi:https://doi.org/10.2217/cns.14.29

Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas

Vincent A. van Vugt, David E. Piccioni, Bradley D. Brown, Tiffany Brown, Marlon G. Saria, Tiffany Juarez, Santosh Kesari

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

AIMS: We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.

PATIENTS & METHODS: Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2).

RESULTS: We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response.

CONCLUSION: The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.

Original language	English
Pages (from-to)	257-265
Number of pages	9
Journal	CNS oncology
Volume	3
Issue number	4
DOIs	https://doi.org/10.2217/cns.14.29
Publication status	Published - 1 Jul 2014
Externally published	Yes

Keywords

alternative regimens
chemotherapy
glioblastoma
glioma temodar
safety
temozolomide

Access to Document

https://doi.org/10.2217/cns.14.29

Cite this

@article{671c0180932944168efff68bcde56bbb,

title = "Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas",

abstract = "AIMS: We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.PATIENTS & METHODS: Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2).RESULTS: We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response.CONCLUSION: The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.",

keywords = "alternative regimens, chemotherapy, glioblastoma, glioma temodar, safety, temozolomide",

author = "{van Vugt}, {Vincent A.} and Piccioni, {David E.} and Brown, {Bradley D.} and Tiffany Brown and Saria, {Marlon G.} and Tiffany Juarez and Santosh Kesari",

year = "2014",

month = jul,

day = "1",

doi = "https://doi.org/10.2217/cns.14.29",

language = "English",

volume = "3",

pages = "257--265",

journal = "CNS oncology",

issn = "2045-0907",

publisher = "Future Medicine Ltd.",

number = "4",

}

TY - JOUR

T1 - Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas

AU - van Vugt, Vincent A.

AU - Piccioni, David E.

AU - Brown, Bradley D.

AU - Brown, Tiffany

AU - Saria, Marlon G.

AU - Juarez, Tiffany

AU - Kesari, Santosh

PY - 2014/7/1

Y1 - 2014/7/1

N2 - AIMS: We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.PATIENTS & METHODS: Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2).RESULTS: We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response.CONCLUSION: The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.

AB - AIMS: We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.PATIENTS & METHODS: Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2).RESULTS: We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response.CONCLUSION: The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.

KW - alternative regimens

KW - chemotherapy

KW - glioblastoma

KW - glioma temodar

KW - safety

KW - temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84964313797&partnerID=8YFLogxK

U2 - https://doi.org/10.2217/cns.14.29

DO - https://doi.org/10.2217/cns.14.29

M3 - Article

C2 - 25286037

SN - 2045-0907

VL - 3

SP - 257

EP - 265

JO - CNS oncology

JF - CNS oncology

IS - 4

ER -

Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas

Abstract

Keywords

Access to Document

Other files and links

Cite this